Trinity Capital Inc. Invests $30 Million in Iantrek for Commercial Growth and Product Development
In a remarkable move set to transform the landscape of medical technology, Trinity Capital Inc. is investing $30 million in Iantrek, a pioneering company specializing in bio-interventional ophthalmic surgery (BIOS). This strategic financing aims to expedite Iantrek's commercial expansion and advance its innovative product pipeline, primarily targeting treatments for chronic eye diseases such as glaucoma.
Iantrek has developed a suite of minimally invasive surgical tools designed to enhance the natural fluid outflow pathways of the eye, thereby alleviating ocular pressure. Their technology embodies a convergence of advanced instrumentation and biologic tissue solutions that enable micro-interventional procedures, promising improved patient outcomes.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expressed enthusiasm about the equation of Iantrek's innovative technological capabilities and robust clinical evidence that underpin their early commercial successes. He stated, "We believe Iantrek's innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology. We are pleased to support their team as they enter this next phase of rapid growth."
This funding decision follows Iantrek's previous success with a Series C financing round that secured significant equity investments from key firms including USVP, Sectoral, aMoon, and Visionary Ventures. The new capital will be instrumental in supporting Iantrek’s efforts to increase its commercial reach, enhance product development, and improve regulatory efforts for its pipeline offerings. Additionally, it will assist in scaling production and boosting market access initiatives that are vital for expanding both physician and patient adoption of their cutting-edge technologies.
Adam Szaronos, CEO of Iantrek, remarked that securing this financing is a pivotal strategy in responding to the surging demand from physicians for their innovative platform. He emphasized that the investment will facilitate the acceleration of their flagship technology, AlloFlo Uveo, and advance the development of pioneering bio-interventional procedures aimed at providing better surgical solutions for glaucoma patients.
Trinity Capital Inc. is renowned for its role as an international alternative asset manager, delivering consistent returns for investors by providing access to private credit markets. The company is committed to sourcing and structuring investments tailored to growth-oriented companies across various sectors, primarily focusing on Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences. Since its inception in 2008, Trinity has successfully deployed over $5.5 billion across more than 463 investments, attesting to its reputation as a trusted partner for innovative companies.
With headquarters in Phoenix, Arizona, Trinity Capital has established a strong presence across the U.S. and Europe, ensuring a comprehensive support system for the companies they invest in. For those interested in learning more about Trinity Capital and its strategic vision, details can be found at trinitycapital.com.
Iantrek, conversely, is at the forefront of developing groundbreaking technologies aimed at bio-interventional ophthalmic surgery. Through innovative procedures that focus on restoring natural ocular outflow, Iantrek is reshaping the treatment landscape for chronic eye diseases. Following the launch of their product AlloFlo Uveo in October 2025 and their upcoming U.S. introduction of AlloSpan Canal, Iantrek will uniquely provide complementary surgical solutions, targeting natural outflow pathways for a holistic approach to glaucoma treatment. Additional information regarding Iantrek and its offerings is available at iantrekmed.com.
As the healthcare sector continues to evolve, such partnerships illustrate the vital role of strategic financing in fostering innovation and improving patient care. The anticipated growth trajectory of Iantrek, bolstered by this significant investment from Trinity, indeed sends a hopeful message in the realm of medical technology.
Iantrek has developed a suite of minimally invasive surgical tools designed to enhance the natural fluid outflow pathways of the eye, thereby alleviating ocular pressure. Their technology embodies a convergence of advanced instrumentation and biologic tissue solutions that enable micro-interventional procedures, promising improved patient outcomes.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expressed enthusiasm about the equation of Iantrek's innovative technological capabilities and robust clinical evidence that underpin their early commercial successes. He stated, "We believe Iantrek's innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology. We are pleased to support their team as they enter this next phase of rapid growth."
This funding decision follows Iantrek's previous success with a Series C financing round that secured significant equity investments from key firms including USVP, Sectoral, aMoon, and Visionary Ventures. The new capital will be instrumental in supporting Iantrek’s efforts to increase its commercial reach, enhance product development, and improve regulatory efforts for its pipeline offerings. Additionally, it will assist in scaling production and boosting market access initiatives that are vital for expanding both physician and patient adoption of their cutting-edge technologies.
Adam Szaronos, CEO of Iantrek, remarked that securing this financing is a pivotal strategy in responding to the surging demand from physicians for their innovative platform. He emphasized that the investment will facilitate the acceleration of their flagship technology, AlloFlo Uveo, and advance the development of pioneering bio-interventional procedures aimed at providing better surgical solutions for glaucoma patients.
Trinity Capital Inc. is renowned for its role as an international alternative asset manager, delivering consistent returns for investors by providing access to private credit markets. The company is committed to sourcing and structuring investments tailored to growth-oriented companies across various sectors, primarily focusing on Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences. Since its inception in 2008, Trinity has successfully deployed over $5.5 billion across more than 463 investments, attesting to its reputation as a trusted partner for innovative companies.
With headquarters in Phoenix, Arizona, Trinity Capital has established a strong presence across the U.S. and Europe, ensuring a comprehensive support system for the companies they invest in. For those interested in learning more about Trinity Capital and its strategic vision, details can be found at trinitycapital.com.
Iantrek, conversely, is at the forefront of developing groundbreaking technologies aimed at bio-interventional ophthalmic surgery. Through innovative procedures that focus on restoring natural ocular outflow, Iantrek is reshaping the treatment landscape for chronic eye diseases. Following the launch of their product AlloFlo Uveo in October 2025 and their upcoming U.S. introduction of AlloSpan Canal, Iantrek will uniquely provide complementary surgical solutions, targeting natural outflow pathways for a holistic approach to glaucoma treatment. Additional information regarding Iantrek and its offerings is available at iantrekmed.com.
As the healthcare sector continues to evolve, such partnerships illustrate the vital role of strategic financing in fostering innovation and improving patient care. The anticipated growth trajectory of Iantrek, bolstered by this significant investment from Trinity, indeed sends a hopeful message in the realm of medical technology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.